LSV Asset Management Decreases Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

LSV Asset Management decreased its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 1.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,343,227 shares of the specialty pharmaceutical company’s stock after selling 28,950 shares during the period. LSV Asset Management’s holdings in Jazz Pharmaceuticals were worth $288,217,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Covestor Ltd boosted its stake in Jazz Pharmaceuticals by 676.5% during the third quarter. Covestor Ltd now owns 396 shares of the specialty pharmaceutical company’s stock valued at $51,000 after buying an additional 345 shares during the last quarter. Spire Wealth Management boosted its position in shares of Jazz Pharmaceuticals by 128.6% during the 3rd quarter. Spire Wealth Management now owns 423 shares of the specialty pharmaceutical company’s stock valued at $55,000 after acquiring an additional 238 shares during the last quarter. Headinvest LLC purchased a new position in shares of Jazz Pharmaceuticals in the third quarter valued at $56,000. Signaturefd LLC increased its position in Jazz Pharmaceuticals by 85.7% in the third quarter. Signaturefd LLC now owns 546 shares of the specialty pharmaceutical company’s stock worth $71,000 after purchasing an additional 252 shares during the last quarter. Finally, Headlands Technologies LLC purchased a new stake in Jazz Pharmaceuticals during the third quarter valued at $78,000. 89.14% of the stock is owned by institutional investors.

Insider Activity

In other Jazz Pharmaceuticals news, CFO Philip L. Johnson acquired 12,000 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were bought at an average cost of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the acquisition, the chief financial officer now directly owns 27,932 shares in the company, valued at approximately $3,342,063.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CFO Philip L. Johnson acquired 12,000 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The stock was purchased at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the purchase, the chief financial officer now directly owns 27,932 shares of the company’s stock, valued at approximately $3,342,063.80. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Patricia Carr sold 1,936 shares of the business’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the transaction, the chief accounting officer now owns 8,364 shares of the company’s stock, valued at $1,000,668.96. The disclosure for this sale can be found here. Company insiders own 4.40% of the company’s stock.

Jazz Pharmaceuticals Trading Up 0.7 %

NASDAQ:JAZZ traded up $0.72 during midday trading on Friday, hitting $110.01. The stock had a trading volume of 693,769 shares, compared to its average volume of 597,957. The company has a quick ratio of 1.85, a current ratio of 2.27 and a debt-to-equity ratio of 1.38. The stock has a 50-day moving average of $116.44 and a 200 day moving average of $121.02. The company has a market capitalization of $6.94 billion, a price-to-earnings ratio of 22.68, a PEG ratio of 1.52 and a beta of 0.63. Jazz Pharmaceuticals plc has a one year low of $103.01 and a one year high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing the consensus estimate of $4.44 by ($0.04). Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1.01 billion. As a group, sell-side analysts forecast that Jazz Pharmaceuticals plc will post 16.24 EPS for the current year.

Wall Street Analyst Weigh In

JAZZ has been the subject of a number of recent research reports. Barclays dropped their price objective on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Friday. Needham & Company LLC reiterated a “buy” rating and issued a $222.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $180.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, April 10th. Piper Sandler boosted their target price on Jazz Pharmaceuticals from $171.00 to $188.00 and gave the company an “overweight” rating in a research report on Wednesday, March 20th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $195.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, February 29th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $192.75.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.